Turnstone biologics corp
TSBX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
TSBX 近期報酬表現
-
Turnstone biologics corp
2.06%
同產業平均
-0.34%
S&P500
與 TSBX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
PSTV | Plus therapeutics inc | 4 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
BCDA | Biocardia inc | 3 分 | 1 分 | 2 分 | 1 分 | 1 分 | |
SPRO | Spero therapeutics inc | 4 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
RARE | Ultragenyx pharmaceutical inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
LYEL | Lyell immunopharma inc | - | 3 分 | 3 分 | 3 分 | 1 分 |
- PSTV Plus therapeutics inc價值 4 分趨勢 2 分波段 2 分籌碼 1 分股利 1 分查看更多
TSBX 公司資訊
Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient's tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.